Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 7/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158065 | 0.85 | CES1 (0.45) | HDAC1HDAC2CES1NPY1RBCAT2 | |
| SCHEMBL4158024 | 0.85 | HDAC1 (0.38) | HDAC1HDAC2CES1NPY1RCCR2 | |
| SCHEMBL4161122 | 0.83 | NPC1 (0.46) | HDAC1HDAC2CES1NPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4169533 | 0.82 | MAPT (0.41) | — | |
| SCHEMBL4159834 | 0.78 | EPHX2 (0.43) | HDAC1HDAC2NPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4166937 | 0.78 | FABP4 (0.36) | HDAC1HDAC2CES1SMN1; SMN2 | |
| SCHEMBL4620748 | 0.77 | LMNA (0.40) | SMN1; SMN2 | |
| SCHEMBL4166649 | 0.77 | HDAC1 (0.38) | HDAC1HDAC2CES1ASAH1NPY1R | |
| SCHEMBL4159674 | 0.75 | HDAC1 (0.42) | HDAC1HDAC2CES1ASAH1BCAT2 | |
| Trifluoroacetic Acid SCHEMBL4304780 | 0.70 | CES1 (0.50) | HDAC1HDAC2CES1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054448-A1 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors | JONES PHILIP | 2009-02-26 | — | — | US | disclosed |
| EP-1945609-A2 | AMINO ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007029036-A2 | AMINO ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054448-A1 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC5, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 7/4885CES1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.